Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00101608
Recruitment Status : Completed
First Posted : January 13, 2005
Last Update Posted : March 2, 2010
Pierre Fabre Medicament
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium. The safety of this treatment will also be studied.

Condition or disease Intervention/treatment Phase
Transitional Cell Carcinoma Bladder Neoplasms Kidney Neoplasms Ureter Neoplasms Bladder Cancer Neoplasm, Bladder Drug: vinflunine Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Study Start Date : January 2005
Actual Primary Completion Date : April 2007
Actual Study Completion Date : April 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: vinflunine
solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration

Primary Outcome Measures :
  1. To estimate the objective response rate in patients with TCC of the urothelium receiving vinflunine, who had evidence of documented progression at any time within 12 months after the last dose of platinum therapy and are not candidates of cystectomy. [ Time Frame: 10-Apr-2007 ]

Secondary Outcome Measures :
  1. To estimate duration of response, time to response disease control rate, progression free survival, and overall survival in this patient population, and evaluate the safety profile of vinflunine [ Time Frame: 10-April-2007 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic (i.e. patients cannot be candidates for local/regional control of disease).
  • Relapse or progression within 12.5 months of prior cisplatin or carboplatin containing chemotherapy regimen.
  • Adequate performance status (Karnofsky greater or equal to 80).

Exclusion Criteria:

  • Receipt of more than 1 prior chemotherapy regimen in any setting.
  • Prior discontinuation of platinum due solely to toxicity.
  • Current neuropathy greater or equal to CTC grade 2.
  • Prior radiation to greater or equal to 30% of bone marrow.
  • Inadequate hematologic function: ANC <1,500 cells/mm3, Platelet<100,000 cells/mm3.
  • Inadequate hepatic function: total bilirubin > 1.5 times ULN, ALT/AST > 2.5 times ULN or > 5 times ULN in case of liver metastasis.
  • Inadequate renal function: creatinine clearance <20 ml/min.
  • Prior allergy to any vinca-alkaloid.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00101608

  Hide Study Locations
United States, California
Local Institution
Beverly Hills, California, United States
Local Institution
La Jolla, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
Santa Monica, California, United States
Local Institution
Stanford, California, United States
Local Institution
Vallejo, California, United States
United States, Colorado
Local Institution
Aurora, Colorado, United States
United States, Connecticut
Local Institution
New Haven, Connecticut, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Jacksonville, Florida, United States
Local Institution
Miami, Florida, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
Local Institution
Joliet, Illinois, United States
Local Institution
Urbana, Illinois, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Maryland
Local Institution
Baltimore, Maryland, United States
United States, Massachusetts
Local Institution
Burlington, Massachusetts, United States
United States, Michigan
Local Institution
Ann Arbor, Michigan, United States
Local Institution
Detroit, Michigan, United States
United States, Missouri
Local Institution
Kansas City, Missouri, United States
Local Institution
St. Louis, Missouri, United States
United States, Nevada
Local Institution
Las Vegas, Nevada, United States
United States, New Hampshire
Local Institution
Lebanon, New Hampshire, United States
United States, New York
Local Institution
Bronx, New York, United States
Local Institution
Buffalo, New York, United States
Local Institution
New York, New York, United States
United States, North Carolina
Local Institution
Charlotte, North Carolina, United States
Local Institution
Durham, North Carolina, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Pittsburgh, Pennsylvania, United States
United States, Rhode Island
Local Institution
Providence, Rhode Island, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
United States, Texas
Local Institution
Dallas, Texas, United States
United States, Washington
Local Institution
Seattle, Washington, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States
Australia, New South Wales
Local Institution
Liverpool, New South Wales, Australia
Local Institution
Sydney, New South Wales, Australia
Local Institution
Taree, New South Wales, Australia
Local Institution
Waratah, New South Wales, Australia
Local Institution
Westmead, New South Wales, Australia
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia
Local Institution
Linz, Austria
Local Institution
Salzburg, Austria
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada
Canada, Ontario
Local Institution
London, Ontario, Canada
Local Insitution
Toronto, Ontario, Canada
Canada, Quebec
Local Institution
Montreal, Quebec, Canada
Local Institution
Caen, France
Local Institution
Le Mans Cedex 2, France
Local Institution
Nice, France
Local Institution
Paris, France
Local Institution
Toulouse, France
Local Institution
Ilion, Greece
Local Institution
Jakarta, Indonesia
Local Institution
Genova, Italy
Local Institution
Milan, Italy
Local Institution
Roma, Italy
Local Institution
Rome, Italy
Local Institution
Viterbo, Italy
Korea, Republic of
Local Institution
Seoul, Korea, Republic of
Local Institution
Cebu City, Philippines
Local Institution
Quezon City, Philippines
Local Institution
Quezon, Philippines
Local Institution
Singapore, Singapore
Local Institution
Murcia, Spain
Local Institution
Palma De Mallorca, Spain
Local Institution
Santander, Spain
Local Institution
Sevilla, Spain
Local Institution
Linkoping, Sweden
Local Institution
Uppsala, Sweden
Local Institution
Aarau, Switzerland
Local Institution
Bangkok, Thailand
Sponsors and Collaborators
Bristol-Myers Squibb
Pierre Fabre Medicament
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Responsible Party: Study Director, Bristol-Myers Squibb Identifier: NCT00101608     History of Changes
Obsolete Identifiers: NCT00268424
Other Study ID Numbers: CA183-001
First Posted: January 13, 2005    Key Record Dates
Last Update Posted: March 2, 2010
Last Verified: August 2008

Keywords provided by Bristol-Myers Squibb:

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Kidney Neoplasms
Ureteral Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Kidney Diseases
Ureteral Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action